Clinical Trial Search

Phase 3 N=467 A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)

Type 2 Diabetes Mellitus

Primary: Change From Baseline in Hemoglobin A1C (HbA1C) Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin — -0.67; -0.32 A1C % — p=<0.001

Merck Sharp & Dohme LLC Results Jan 2015 2.8% serious AE View details

Phase 3 N=961 Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

Papulopustular Rosacea

Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward) — 32.1…

LEO Pharma Results Jan 2015 0.7% serious AE View details

Phase 3 N=48 Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Acquired Immunodeficiency Syndrome · HIV Infections

Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 — 100.0 percentage of participants

Gilead Sciences Results Jan 2015 2.1% serious AE View details

Phase 3 N=438 Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Acquired Immunodeficiency Syndrome · HIV Infections

Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 — 93.8; 87.1 percentage of participants — p=0.025

Gilead Sciences Results Jan 2015 7.9% serious AE View details

Phase 3 N=172 THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation

Heart Diseases · Arrhythmia · Atrial Fibrillation

Primary: The Rate of Subjects Who Were Free From Documented Symptomatic Atrial Fibrillation (AF), Atrial Tachycardia (AT), or Atrial Flutter (AFL) Episodes Through 12-month…

Biosense Webster, Inc. Results Jan 2015 23.6% serious AE View details

Phase 3 N=610 A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty

Prevention · Venous Thromboembolism

Primary: Incidence of Subjects With Venous Thromboembolism Events — 2.4; 6.9 percentage of subjects with vte events — p=<0.001

Daiichi Sankyo Co., Ltd. Results Jan 2015 3.0% serious AE View details

Phase 3 N=357 Bimatoprost for the Treatment of Eyebrow Hypotrichosis

Eyebrow Hypotrichosis

Primary: Percentage of Participants With at Least a 1-Grade Increase (Improvement) in the 4-Point Global Eyebrow Assessment (GEBA) Scale — 83.9; 77.1; 43.0 percentage of…

Allergan Results Jan 2015 2.0% serious AE View details

Phase 3 N=492 Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Depression

Primary: Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30) — -18.8; -20.9; -20.7 units on a…

Cephalon Results Jan 2015 1.6% serious AE View details

Phase 3 N=93 Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment

Non-valvular Atrial Fibrillation

Primary: Incidence of Any Adjudicated Bleeding Events — 20.0; 22.7; 23.8 percentage of subjects with bleeds

Daiichi Sankyo Co., Ltd. Results Jan 2015 5.4% serious AE View details

Phase 3 N=399 Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Depression

Primary: Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30) — -19.4; -20.8 units on a scale…

Cephalon Results Jan 2015 2.8% serious AE View details

Phase 3 N=364 BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung · Adenocarcinoma

Primary: Progression-free Survival — 11.01; 5.59 months — p=<0.0001

Boehringer Ingelheim Results Jan 2015 14.8% serious AE View details

Phase 3 N=433 A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Depression

Primary: Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30) — -17.9; -21.7; -20.8 units on a…

Cephalon Results Jan 2015 2.3% serious AE View details

Phase 3 N=978 A Study in Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Primary: Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) — -1.51; -1.30; -0.99; -0.46 percentage of glycosylated hemoglobin — p=<0.001

Eli Lilly and Company Results Jan 2015 7.0% serious AE View details

Phase 3 N=119 Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity

Dentine Hypersensitivity

Primary: Mean Change From Baseline in Schiff Sensitivity Score — 2.26; 2.25; 2.09; 0.78 Score on a scale — p=<0.0001

GlaxoSmithKline Results Jan 2015 0.0% serious AE View details

Phase 3 N=92 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery

Venous Thromboembolism

Primary: The Incidence of Major or Clinically Relevant Non-major Bleeding — 3.4; 6.9 percentage of subjects with bleeds

Daiichi Sankyo Co., Ltd. Results Jan 2015 6.8% serious AE View details